Table 4. Association between CYP4F2 polymorphisms and histological response.

	Response	Entire cohort							Vit E treated group
		V433M				W12G			V433M				W12G
		MM	VM	VV	p	GG+WG	WW	p	MM	VM	VV	p	GG+WG	WW	p
PIVENS
Overall improvement	Y	3	25	44	ns	33	63	ns	2	14	15	ns	10	22	ns
	N	9	36	51		19	54		0	14	15		10	19
Resolution of NASH	Y	5	26	41	ns	19	54	ns	1	10	15	ns	6	21	ns
	N	10	46	66		41	81		2	19	22		15	28
Improvement in
- Steatosis	Y	8	40	49	ns	32	66	ns	2	15	19	ns	12	25	ns
	N	7	32	58		28	69		1	14	18		9	24
- Inflammation	Y	7	34	53	ns	28	67	ns	1	17	19	ns	11	27	ns
	N	8	38	54		32	68		2	12	18		10	22
- Ballooning	Y	4	30	49	ns	24	60	ns	2	18	15	ns	13	23	ns
	N	11	42	58		36	75		1	11	22		8	26
- Fibrosis	Y	7	24	39	ns	21	49	ns	1	12	15	ns	7	21	ns
	N	8	48	67		39	85		2	17	21		14	27
TONIC
Overall improvement	Y	6	16	30	ns	17	35	ns	4	4	11	ns	4	15	ns
	N	4	29	53		16	71		3	6	17		2	25
Resolution of NASH	Y	5	13	31	ns	10	39	ns	5	6	12	ns	4	19	ns
	N	5	23	37		17	49		2	3	11		2	15
Improvement in
- Steatosis	Y	6	21	41	ns	19	49	ns	4	5	16	ns	3	22	ns
	N	4	25	42		14	58		3	6	12		3	19
- Inflammation	Y	4	21	38	ns	13	49	ns	3	5	13	ns	3	18	ns
	N	6	26	45		20	58		4	6	15		3	23
- Ballooning	Y	4	9	36	0.024	7	42	ns	3	4	13	ns	2	18	ns
	N	6	37	47		26	65		4	7	15		4	23
- Fibrosis	Y	8	18	28	0.018	17	38	ns	5	4	7	ns	4	13	ns
	N	2	27	55		16	68		2	6	21		2	27